Siludi Pharmaceutical Co., Ltd. announced that the joint project 3D189 between the company and SELLAS was used in the global critical phase III REGAL trial to treat acute myeloid leukemia. As of October 28, 2026, the planned 80 cases had been reached, triggering the final analysis. SELLAS will carry out database locking, research data disclosure and statistical analysis of key endpoint data. After completion, the preliminary top-line results of the main endpoints will be announced this quarter based on the statistical analysis plan pre-formulated for the test.

Siludi Pharmaceutical Co., Ltd. announced that the joint project 3D189 between the company and SELLAS was used in the global critical phase III REGAL trial to treat acute myeloid leukemia. As of October 28, 2026, the planned 80 cases had been reached, triggering the final analysis. SELLAS will carry out database locking, research data disclosure and statistical analysis of key endpoint data. After completion, the preliminary top-line results of the main endpoints will be announced this quarter based on the statistical analysis plan pre-formulated in the test.